ArticleBritish journal of cancer2026
Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic options are limited for patients with high-grade ovarian carcinoma (HGOC) progressing after poly(adenosine diphosphate-ribose) polymerase-inhibitor (PARPi). WEE1/CDK2-inhibitors efficacy is under investigation in HGOC harbouring CCNE1 amplification/Cyclin E1 overexpression. However, Cyclin E1 expression evolution after PARPi has not been studied. We aimed to describe Cyclin E1 expression/CCNE1 copy number in post-PARPi HGOC samples and compare to paired samples from diagnosis and/or post-neoadjuvant chemotherapy (post-NACT).
methodsThirty-eight patients with available post-PARPi samples were included; paired samples from diagnosis (n = 26) and/or post-NACT (n = 24) were collected. Cyclin E1 expression was quantified using immunohistochemistry (IHC). CCNE1 copy number was evaluated using fluorescent in situ hybridisation (FISH).
resultsSeventy-two percent (26/36) of HGOC were homologous recombination deficient. Intratumoral Cyclin E1 expression was homogenous in samples from synchronous but anatomically distinct tumour sites. However, Cyclin E1 expression increased significantly between diagnosis and progression post-PARPi (median H-score = 113 versus 163, respectively; p = 0.034). The proportion of Cyclin E1-high (H-score ≥ 150) tumours was 31% (8/26) at diagnosis, 42% (10/24) post-NACT, and increased significantly to 61% (23/38) post-PARPi (versus diagnosis; p = 0.024). In contrast, only 10% (2/20) of Cyclin E1-high HGOC exhibited CCNE1 amplification ( ≥ 8 CCNE1 copies).
conclusionsCyclin E1 expression in HGOC increases at post-PARPi progression, independently of CCNE1 amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.